This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
This month, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), trade groups representing the biopharmaceutical and biotechnology industries, announced that they are challenging Nevada’s Senate Bill (SB) 539 in district court litigation.
Passed in June 2017 by constitutional majorities in both the Nevada Assembly and Senate, the bill was signed into law by Governor Brian Sandoval (R). Among other provisions, the law requires drug manufacturers to annually disclose list prices set for insulins, profits made, and discounts provided to pharmacy benefit managers (PBMs). It also requires drug makers to explain insulin price increases that are above the prior year’s inflation rate (or twice the inflation rate of the past 2 years).
Manufacturers could face daily fines if they fail to provide the required data. The bill also permits pharmacists to provide patients with information about lower-priced alternative prescription options.
According to the groups’ complaint, the “unprecedented and unconstitutional Nevada law… interferes with the federal patent and trade-secret laws, deprives manufacturers of their property interest in their trade secrets, and improperly overrides the regulatory choices of every other state.” PhRMA and BIO are seeking a declaration from the court that sections of SB 539 are preempted by federal law, and that they violate the US Constitution. They also seek a preliminary and permanent injunction prohibiting implementation or enforcement of the provisions at issue.
“While the purpose of the Act is to control prices for diabetes drugs, neither the Act nor its legislative history explain how transparency will lower prices apart from impermissibly burdening manufacturers’ lawful exercise of federal patent rights. The Constitution entrusts national economic policy to Congress precisely to avoid such outcomes,” according to the group’s complaint.
Governor Sandoval said that the suit did not come as a surprise to his office, and that the state’s attorney general would “vigorously defend this existing state law which was passed with bipartisan majorities of both houses.”
Nevada’s law is not the only state-based drug pricing initiative to find itself the target of a lawsuit this month; trade group the Association for Accessible Medicines has filed a suit in Maryland, claiming that the state’s House Bill (HB) 631 is unconstitutional.
HB 631, originally slated to take effect next month, would require the Maryland Medical Assistance Program to notify the state’s attorney general of increase in the prices of generic or off-patent treatments, and would authorize the attorney general to both demand drug makers’ records and impose penalties on manufacturers who violate the law.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.